German medical diagnostic instrument manufacturer HEINE Optotechnik is strengthening its presence in India through a new five-year exclusive distribution agreement with QMS Medical Allied Services Limited.
Beginning January 1, 2027, QMS will become HEINE’s sole distributor in India for a broad portfolio of diagnostic instruments and related products. Under the agreement, HEINE will not supply or appoint other distributors, dealers or commercial partners in the country for the products covered by the arrangement.
The agreement represents a significant change in HEINE’s approach to the Indian market. The company expects to generate approximately €2.6 million, in India revenue during 2026. QMS says it expects sales from the HEINE business to exceed €6 million by 2031, which would represent more than a doubling of the current business over five years.
Based in Gilching, near Munich, HEINE manufactures primary diagnostic instruments used by physicians and other healthcare professionals. Its product range includes otoscopes, ENT instruments, dermatoscopes, ophthalmic instruments, laryngoscopes, medical loupes and headlights, as well as digital documentation systems. The agreement also covers veterinary diagnostic instruments, power sources, spare parts and other specialized products.
The deal was signed at HEINE’s headquarters in Germany by Time Martin, Chief Operations Officer of HEINE Optotechnik, and Allan Dabreo, General Manager of the Hospital & Distribution Division at QMS.
For HEINE, concentrating its India business with one distributor might provide a more coordinated approach to sales, customer support and market development across a large and fragmented healthcare market. For other medical device companies, it sometimes make sense to appoint multiple partners across India – by region, by vertical market or by type of customer (government, corporate etc.). In fact much of Amritt’s market entry and expansion work revolves around precisely this analysis.
Mumbai-based QMS already distributes medical products in India and expects to use its existing sales and distribution network to expand HEINE’s reach. QMS Chairman and Managing Director Mahesh Makhija said the HEINE partnership will be an important part of the company’s product business expansion over the next five years. The agreement is also another example of an international medical device manufacturer choosing a local distribution partnership rather than establishing a wholly owned commercial organization to expand in India.
For overseas medical device companies, India presents a sizable opportunity but also requires extensive local market coverage. Hospitals, private clinics and individual practitioners are spread across numerous metropolitan and regional markets, while sales of specialized clinical products frequently depend on product demonstrations, clinician relationships, training and after-sales support.
HEINE’s decision to consolidate its Indian business under an exclusive five-year agreement suggests that the company sees sufficient long-term opportunity in the market to commit to a more structured national distribution strategy.
